FAIRMOUNT FUNDS MANAGEMENT LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

08/15/2024

Adviser Type:

- Large advisory firm

Number of Employees:

21 110.00%

of those in investment advisory functions:

11 83.33%

Registration:

SEC, Approved, 6/27/2019

Other registrations (1)
Former registrations

FAIRMOUNT FUNDS MANAGEMENT LLC

AUM:

2,276,508,000 53.71%

of that, discretionary:

2,276,508,000 53.71%

Private Fund GAV:

2,301,956,688 49.98%

Avg Account Size:

569,127,000 92.14%

SMA’s:

NO

Private Funds:

4 1

Contact Info

267 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
1B 1B 1B 846M 635M 423M 212M
2019 2020 2021 2022 2023

Recent News

Fairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd
08/11/2023

Related Stocks: KNSA, AXSM, BGNE, VRNA, NUVL, ELVN,

gurufocus.com

Neoleukin Therapeutics Inc.
03/26/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

KLAR Partners closes debut fund at its hard cap of €600 million
03/23/2021

STOCKHOLM, March 23, 2021 /PRNewswire/ -- KLAR Partners ("KLAR" or "Firm") today announced the final closing of its debut fund, KLAR Partners I ("KLAR I" or the "Fund"), at its hard cap of €600 ...

yahoo.com

KLAR Partners closes debut fund at its hard cap of €600 million
03/23/2021

STOCKHOLM, March 23, 2021 /PRNewswire/ -- KLAR Partners ("KLAR" or "Firm") today announced the final closing of its debut fund, KLAR Partners I ("KLAR I" or the "Fund"), at its hard cap of €600 ...

yahoo.com

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
03/23/2021

Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds Management LLC (“Fairmount”) and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital ...

Yahoo Finance

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
03/23/2021

Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds Management LLC (“Fairmount”) and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital ...

Yahoo Finance


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $2,250,924,000
Private Equity Fund 3 $51,032,688

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
P2 CAPITAL PARTNERS, LLC 985.6m - 333.4m - - - - 1.3b 1.3b 2
LONG PATH PARTNERS, LP 627.3m - 274.8m - - - - 902.2m 1.0b 5
VENOR CAPITAL MANAGEMENT LP 300.3m - 114.1m - - - - 414.4m 439.5m 5
PERINI CAPITAL 32.6m - 44.2m - - - - 76.9m 161.0m 7
LUTHER KING CAPITAL MANAGEMENT CORPORATION 2.2b - 4.3b - - - - 6.5b 30.5b 16
ALTERNATIVE INVESTMENT MANAGEMENT, LLC 721.3m - 415.0m - - - - 1.1b 1.5b 20
SUMMIT ROCK ADVISORS, LP 7.4b - 4.6b - - - - 12.0b 21.5b 20
XN LP 3.0b - 253.8m - - - - 3.3b 3.3b 8
PARIAN GLOBAL MANAGEMENT LP - - - - - - - - - -
EOS MANAGEMENT, L.P. 745.8m - 718.6m - - - - 1.5b 1.5b 7

Private Funds



Employees




Brochure Summary

Overview

Fairmount Funds Management LLC, a Delaware limited liability company (hereinafter “Fairmount,” “we”, “us”, “our” or the “Firm”), was founded by Peter Harwin and Tomas Kiselak, the principal owners of the Firm (the “Managing Members”) in August 2016. The Managing Members are responsible for the Firm’s daily management and portfolio selection. Fairmount Healthcare Fund II GP LLC and Fairmount Healthcare Co-Invest II GP LLC both Delaware limited liability companies (the “General Partners”), are affiliated with the Firm and owned by the Managing Members. Fairmount provides discretionary investment management services to qualified investors through its privately placed pooled investment vehicles (the “Funds”): (i) Fairmount Healthcare Fund II LP (“Fairmount Healthcare Fund II”) and Fairmount Healthcare Feeder Fund II LP (“Offshore Fund II,” and together with Fairmount Healthcare Fund II, the “Partnerships”); (ii) one Special Purpose Vehicle (the “SPV”); and (iii) Fairmount Healthcare Co-Invest II LP (“Co-invest II”). Offshore Fund II invests all its assets in Fairmount Healthcare Fund II. Offshore Fund II’s shareholders, Fairmount Healthcare Fund II and Co-invest II’s limited partners, and the members of the
SPV are hereafter collectively referred to as the “Investors” where appropriate. We do not tailor our advisory services to the individual needs of any Investor. Fairmount manages investments primarily focused on healthcare and life science companies, including companies developing drugs, devices, diagnostics, services, and/or healthcare IT. Investments are generally comprised of common stock, preferred shares, warrants, options, baskets of securities, exchange-traded funds, restricted shares, contingent value rights, and investments in privately held companies. We focus on small and midsize market capitalization companies and may invest long and/or short and may choose to hedge some or all of our positions. As of December 31, 2023, the Firm managed approximately $2,277,000,000 in client assets, all of which were managed on a discretionary basis. Information about the Funds presented in this Brochure is indicative of Fund terms and practices. Interests in any Fund are offered to eligible investors only through their respective confidential offering memoranda and other offering and governing documents, which should be read in their entirety prior to investment. This Brochure is not an offer of interests in any Fund.